Peptide Research: Tirzepatide – Studies, Research Use, and Scientific Background

What is Tirzepatide?

Tirzepatide is a synthetic peptide and dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is an investigational compound widely studied in laboratory research for its potential effects on glucose metabolism, weight regulation, and appetite pathways in experimental models.
For laboratory research use only. Not for human or veterinary use.

Key Scientific Studies

  • Dual Agonist Mechanism: Clinical trials published in New England Journal of Medicine (2022) reported that Tirzepatide significantly improved glycemic control and supported body weight reduction in human research subjects by activating both GIP and GLP-1 receptors.
    Frías et al., 2022
  • Preclinical & Laboratory Models: Additional laboratory research has shown Tirzepatide’s role in modulating insulin sensitivity, appetite, and energy expenditure in animal studies and in vitro experiments.
    Coskun et al., 2018

Laboratory Research Applications

  • Exploration of metabolic and endocrine signaling pathways
  • Preclinical models of type 2 diabetes, obesity, and metabolic syndrome
  • Study of appetite regulation, insulin secretion, and glucose tolerance
  • Dual incretin receptor research in animal and in vitro studies

Mechanism of Action (in Research Context)

Tirzepatide functions as a dual GIP and GLP-1 receptor agonist. In laboratory studies, this dual mechanism enhances insulin secretion, improves glucose homeostasis, and supports body weight regulation. Its unique structure enables it to engage multiple metabolic pathways, making it an important peptide for advanced metabolic and endocrinological research.

Reference Dosing Schedules from Published Studies

For Laboratory Reference Only – Not Medical Advice or Guidance

Recent published studies and clinical trials have investigated the following dosing schedules for Tirzepatide in research settings:

  • Initial Dose: 2.5 mg once weekly for the first four weeks
  • Titration: Increased in 2.5 mg increments every four weeks as per protocol
  • Maintenance Dose: Up to 15 mg once weekly, as evaluated in clinical research
References:
Frías JP, et al. New England Journal of Medicine (2022). Read Study
Coskun T, et al. Diabetes (2018). Read Study
ClinicalTrials.gov Identifier: NCT03987919
Important: Endura Lyfe products are for laboratory research use only and are not for human or veterinary use. All information above is cited for scientific reference from published research and is not to be interpreted as medical advice or guidance for human use.
Shopping Cart